CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Peanut OIT +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00815035
NCT00815035Phase 2Completed
CompareCT.gov

Oral Immunotherapy for Peanut Allergy- Peanut Oral Immunotherapy (PnOIT3)

University of North Carolina, Chapel Hill·interventional·Posted Dec 29, 2008·Updated Mar 1, 2018

In Brief

A Phase 2 clinical trial evaluating Peanut OIT and Placebo for Peanut Hypersensitivity. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Hypersensitivity
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 29, 2008
Enrollment StartApr 1, 2009
Primary CompletionDec 12, 2016
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 17.5 years ago

Interventions

Peanut OITdrug

Peanut flour that is orally ingested in a graded fashion.

Placebodrug

Oat flour used as a placebo that is orally ingested a graded fashion